|

GLP-1 receptor agonist Clinical Trials

6 actively recruiting trials across 3 locations

Also known as: GLP-1 agonists, Semaglutide, dulaglutide, exenatide, liraglutide +2 more

Pipeline

Phase 4: 2

Top Sponsors

  • Vanderbilt University Medical Center1
  • University of Missouri-Columbia1
  • The Affiliated Hospital of Xuzhou Medical University1
  • Lia Bally1
  • Cardenal Herrera University1

Indications

  • Diabetes5
  • Obesity2
  • Obstructive Sleep Apnea of Adult1
  • Chronic Kidney Disease Stage 21
  • Chronic Kidney Disease Stage 11

Other3 trials

Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM
N/A
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes
N/A

Baltimore, Maryland1 trial

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Johns Hopkins School of Medicine

Phase 4

Columbia, Missouri1 trial

Impact GLP-1 Agonists Following Bariatric

University of Missouri Hospital

Phase 4

Nashville, Tennessee1 trial

Comparison of Body Composition Changes With Weight Loss Interventions

Vanderbilt University Medical Center

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.